Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
Editor’s note: This is a developing story. Please check back soon for updates.
Epioxa, the first FDA-approved epithelium-on cross-linking procedure, is now commercially available, according to a press release from Glaukos.
The topical therapy offers a streamlined, incision-free treatment for patients with keratoconus, reducing pain associated with epithelium removal and minimizing recovery by using enriched oxygen and light. Epioxa can be ordered from Glaukos or through its specialty pharmaceutical distribution network, according to the release.
Coinciding with the launch, Glaukos announced